Home Food Science and Human Wellness Article
PDF (7.7 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Research Article | Open Access

Alleviatory effect of isoquercetin on benign prostatic hyperplasia via IGF-1/PI3K/Akt/mTOR pathway

Young-Jin Choia,b,c, Meiqi Fand, Nishala Erandi Wedamullaa,b,c,e, Yujiao Tangf, Eun-Kyung Kimg,h()
Department of Food Science and Nutrition, Dong-A University, Busan 49315, Republic of Korea
Center for Silver-targeted Biomaterials, Brain Busan 21 Plus program, Dong-A University, Busan 49315, Republic of Korea
Department of Health Sciences, the Graduate School of Dong-A University, Busan 49315, Republic of Korea
Division of Food Bioscience, College of Biomedical and Health Sciences, Konkuk University, Chungju 27478, Republic of Korea
Department of Export Agriculture, Faculty of Animal Science and Export Agriculture, Uva Wellassa University, Badulla 90000, Sri Lanka
School of Bio-Science and Food Engineering, Changchun University of Science and Technology, Changchun 130600, China
Nutritional Education Major, Graduate School of Education, Dong-A University, Busan 49315, Republic of Korea
Nutrinomics Lab. Co., Ltd., Busan 49315, Republic of Korea

Peer review under responsibility of Tsinghua University Press.

Show Author Information

Abstract

We evaluated the effect of isoquercetin (quercetin-O-3-glucoside-quercetin, IQ) as a functional component of Abeliophyllum disistichum Nakai ethanol extract (ADLE) on prostate cell proliferation and apoptosis and its effects on the IGF-1/PI3K/Akt/mTOR pathway in benign prostatic hyperplasia (BPH). Metabolites in ADLE were analyzed using UHPLC-qTOF-MS and HPLC. IQ was orally administered (1 or 10 mg/kg) to a testosterone propionate-induced BPH rat model, and its effects on the prostate weight were evaluated. The effect of IQ on androgen receptor (AR) signaling was analyzed in LNCaP cells. Whether IGF-1 and IQ affect the IGF-1/PI3K/Akt/mTOR pathway in BPH-1 cells was also examined. The metabolites in ADLE were identified and quantified, which confirmed that ADLE contained abundant IQ (20.88 mg/g). IQ significantly reduced the prostate size in a concentration-dependent manner in a BPH rat model, and significantly decreased the expression of AR signaling factors in the rat prostate tissue and LNCaP cells in a concentration-dependent manner. IQ also inhibited the PI3K/AKT/mTOR pathway activated by IGF-1 treatment in BPH-1 cells. In BPH-1 cells, IQ led to G0/G1 arrest and suppressed the expression of proliferation factors while inducing apoptosis. Thus, IQ shows potential for use as a pharmaceutical and nutraceutical for BPH.

Keywords

IsoquercetinBenign prostatic hyperplasiaAndrogen receptor signalingPI3K/Akt/mtor pathway

References

[1]

A. Ghorbanibirgani, A. Khalili, L. Zamani, The efficacy of stinging nettle (Urtica dioica) in patients with benign prostatic hyperplasia: a randomized double blind study in 100 patients, Iran. Red Crescent Med. J. 15 (2013) 9-10. https://doi.org/10.5812/ircmj.2386.

Crossref Google Scholar
[2]

M.P. O’Leary, Lower urinary tract symptoms/benign prostatic hyperplasia:maintaining symptom control and reducing complications, Urology 62 (2003) 15-23. https://doi.org/10.1016/s0090-4295(03)00480-1.

Crossref Google Scholar
[3]

J.Y. Leong, A.S. Patel, R. Ramasamy, Minimizing sexual dysfunction in BPH surgery, Curr. Sex. Health Rep. 11 (2019) 190-200. https://doi.org/10.1007/s11930-019-00210-1.

Crossref Google Scholar
[4]

K. Kolontarev, A. Govorov, G. Kasyan, et al., Current drug therapy of patients with BPH LUTS with the special emphasis on PDE5 inhibitors, Cent. European J. Urol. 69 (2016) 398-403. https://doi.org/10.5173/ceju.2016.879.

Crossref Google Scholar
[5]

A.W. Partin, J.E. Oesterling, J.I. Epstein, et al., Influence of age and endocrine factors on the volume of benign prostatic hyperplasia, J. Urol. 145 (1991) 405-409. https://doi.org/10.1016/s0022-5347(17)38353-2.

Crossref Google Scholar
[6]

S.E. Dahle, A.P. Chokkalingam, Y.T. Gao, et al, Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia, J. Urol. 168 (2002) 599-604.

Crossref Google Scholar
[7]

J.K. Parsons, H.B. Carter, A.W. Partin, et al., Metabolic factors associated with benign prostatic hyperplasia, J. Clin. Endocrinol. Metab. 91 (2006) 2562-2568. https://doi.org/10.1210/jc.2005-2799.

Crossref Google Scholar
[8]

H. Nandeesha, B.C. Koner, L.N. Dorairajan, et al., Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia, Clin. Chim. Acta. 370 (2006) 89-93. https://doi.org/10.1016/j.cca.2006.01.019.

Crossref Google Scholar
[9]

J. Hammarsten, B. Högstedt, Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia, Blood Press. 8 (1999) 29-36. https://doi.org/10.1080/080370599438365.

Crossref Google Scholar
[10]

A. Ziada, M. Rosenblum, E.D. Crawford, Benign prostatic hyperplasia: an overview, Urology 53 (1999) 1-6. https://doi.org/10.1016/s0090-4295(98)00532-9.

Crossref Google Scholar
[11]

R.E. Vickman, O.E. Franco, D.C. Moline, et al., The role of the androgen receptor in prostate development and benign prostatic hyperplasia: a review, Asian J. Urol. 7 (2020) 191-202. https://doi.org/10.1016/j.ajur.2019.10.003.

Crossref Google Scholar
[12]

T.M. Nicholson, W.A. Ricke, Androgens and estrogens in benign prostatic hyperplasia: past, present and future, Differentiation 82 (2011) 184-199. https://doi.org/10.1016/j.diff.2011.04.006.

Crossref Google Scholar
[13]

P.P. Banerjee, S. Banerjee, T.R. Brown, et al., Androgen action in prostate function and disease, Am. J. Clin. Exp. Urol. 6 (2018) 62-77.

Google Scholar
[14]

T.M. Morgan, T.D. Koreckij, E. Corey, Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway, Curr. Cancer Drug Targets 9 (2009) 237-249. https://doi.org/10.2174/156800909787580999.

Crossref Google Scholar
[15]

N. Ohlson, A. Bergh, P. Stattin, et al., Castration‐induced epithelial cell death in human prostate tissue is related to locally reduced IGF-1 levels, Prostate 67 (2007) 32-40. https://doi.org/10.1002/pros.20480.

Crossref Google Scholar
[16]

E.A. Lesovaya, K.I. Kirsanov, E.E. Antoshina, et al., Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats, Oncotarget 6 (2015) 9718-9727. https://doi.org/10.18632/oncotarget.3929.

Crossref Google Scholar
[17]

D. Liu, J.E. Shoag, D. Poliak, et al., Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes, Nat. Commun. 11 (2020) 1987. https://doi.org/10.1038/s41467-020-15913-6.

Crossref Google Scholar
[18]

Z. Wang, X. Xiao, R. Ge, et al., Metformin inhibits the proliferation of benign prostatic epithelial cells, PloS One 12 (2017) e0173335. https://doi.org/10.1371/journal.pone.0173335.

Crossref Google Scholar
[19]

H.H. Mosli, A. Esmat, R.T. Atawia, et al., Metformin attenuates testosteroneinduced prostatic hyperplasia in rats: a pharmacological perspective, Sci. Rep. 23 (2015) 15639. https://doi.org/10.1038/srep15639.

Crossref Google Scholar
[20]

S.M. Tang, X.T. Deng, J. Zhou, et al., Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects, Biomed. Pharmacother. 121 (2020) 109604. https://doi.org/10.1016/j.biopha.2019.109604.

Crossref Google Scholar
[21]

M. Lesjak, I. Beara, N. Simin, et al., Antioxidant and anti-inflammatory activities of quercetin and its derivatives, J. Funct, Foods 40 (2018) 68-75. https://doi.org/10.1016/j.jff.2017.10.047.

Crossref Google Scholar
[22]

J. Mlcek, T. Jurikova, S. Skrovankova, et al., Quercetin and its anti-allergic immune response, Molecules 21 (2016) 623. https://doi.org/10.3390/molecules21050623.

Crossref Google Scholar
[23]

H.M. Eid, P.S. Haddad, The antidiabetic potential of quercetin: underlying mechanisms, Curr. Med. Chem. 24 (2017) 355-364. https://doi.org/10.2174/0929867323666160909153707.

Crossref Google Scholar
[24]

K.E. Heim, A.R. Tagliaferro, D.J. Bobilya, Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships, J. Nutr. Biochem. 13 (2002) 572-584. https://doi.org/10.1016/S0955-2863(02)00208-5.

Crossref Google Scholar
[25]

Y.J. Choi, M. Fan, Y. Tang, et al., Ameliorative effect of Abeliophyllum distichum Nakai on benign prostatic hyperplasia in vitro and in vivo, Nutr. Res. Pract. 15 (2021) e69. https://doi.org/10.4162/nrp.2022.16.4.419.

Crossref Google Scholar
[26]

I.G. Schauer, D.R. Rowley, The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation 82 (2011) 200-210. https://doi.org/10.1016/j.diff.2011.05.007.

Crossref Google Scholar
[27]

R. Liu, G. Fu, J. Li, et al., Roles of autophagy in androgen-induced benign prostatic hyperplasia in castrated rats, Exp. Ther. Med. 15 (2018) 2703-2710. https://doi.org/10.3892/etm.2018.5772.

Crossref Google Scholar
[28]

Y.S. Won, J.H. Kim, R.C.M. Lizardo, et al., The flavonol isoquercitrin promotes mitochondrial-dependent apoptosis in SK-Mel-2 melanoma cell via the PI3K/AKT/mTOR pathway, Nutrients 12 (2020) 3683. https://doi.org/10.3390/nu12123683.

Crossref Google Scholar
[29]

F. Chen, X. Chen, D. Yang, et al., Isoquercitrin inhibits bladder cancer progression in vivo and in vitro by regulating the PI3K/Akt and PKC signaling pathways, Oncol. Rep. 36 (2016) 165-172. https://doi.org/10.3892/or.2016.4794.

Crossref Google Scholar
[30]

C.Y. Lan, S.Y. Chen, C.W. Kuo, et al., Quercetin facilitates cell death and chemosensitivity through RAGE/PI3K/AKT/mTOR axis in human pancreatic cancer cells, J. Food Drug Anal. 27 (2019) 887-896. https://doi.org/10.1016/j.jfda.2019.07.001.

Crossref Google Scholar
[31]

M. Reyes-Farias, C. Carrasco-Pozo, The anti-cancer effect of quercetin: molecular implications in cancer metabolism, Int. J. Mol. Sci. 20 (2019) 3177. https://doi.org/10.3390/ijms20133177.

Crossref Google Scholar
[32]

A. Bruning, Inhibition of mTOR signaling by quercetin in cancer treatment and prevention, Anticancer Agents Med. Chem. 13 (2013) 1025-1031. https://doi.org/10.2174/18715206113139990114.

Crossref Google Scholar
[33]

N. Xing, Y. Chen, S.H. Mitchell, et al., Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells, Carcinogenesis 22 (2001) 409-414. https://doi.org/10.1093/carcin/22.3.409.

Crossref Google Scholar
[34]

L. Vignozzi, M. Gacci, M. Maggi, Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome, Nat. Rev. Urol. 13 (2016) 108-119. https://doi.org/10.1038/nrurol.2015.301.

Crossref Google Scholar
[35]

S. Kasturi, S. Russell, K.T. McVary, Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia, Curr. Urol. Rep. 4 (2006) 127-131. https://doi.org/10.1007/s11934-996-0008-y.

Crossref Google Scholar
[36]

C. Ozden, O.L. Ozdal, G. Urgancioglu, et al., The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia, Eur. Urol. 51 (2007) 199-206. https://doi.org/10.1016/j.eururo.2006.05.040.

Crossref Google Scholar
[37]

J. Hammarsten, J.E. Damber, M. Karlsson, et al., Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasi, Prostate Cancer Prostatic Dis. 12 (2009) 160-165. https://doi.org/10.1038/pcan.2008.50.

Crossref Google Scholar
[38]

A. Vikram, G. Jena, P. Ramarao, Insulin-resistance and benign prostatic hyperplasia: the connection, Eur. J. Pharmacol. 641 (2010) 75-81. https://doi.org/10.1016/j.ejphar.2010.05.042.

Crossref Google Scholar
[39]

J. Bogdanos, D. Karamanolakis, R. Tenta, et al., Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton, Endocr. Relat. Canc. 10 (2003) 279-289. https://doi.org/10.1677/erc.0.0100279.

Crossref Google Scholar
[40]

Y.C. Kim, K.L. Guan, mTOR: a pharmacologic target for autophagy regulation, J. Clin. Invest. 125 (2015) 25-32. https://doi.org/10.1172/JCI73939.

Crossref Google Scholar
[41]

J.E. Wilkinson, L. Burmeister, S.V. Brooks, et al., Rapamycin slows aging in mice, Aging cell 11 (2012) 675-682. https://doi.org/10.1111/j.1474-9726.2012.00832.x.

Crossref Google Scholar
[42]

M. Hidalgo, E.K. Rowinsky, The rapamycin-sensitive signal transduction pathway as a target for cancer therapy, Oncogene 19 (2000) 6680-6686. https://doi.org/10.1038/sj.onc.1204091.

Crossref Google Scholar
[43]

M. Fraenkel, M. Ketzinel-Gilad, Y. Ariav, et al., mTOR inhibition by rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes, Diabetes 57 (2008) 945-957. https://doi.org/10.2337/db07-0922.

Crossref Google Scholar
[44]

Z.Z. Chong, K. Maiese, Mammalian target of rapamycin signaling in diabetic cardiovascular disease, Cardiovasc. Diabetol. 11 (2012) 1-8. https://doi.org/10.1186/1475-2840-11-45.

Crossref Google Scholar
[45]

L. Shui, W. Wang, M. Xie, et al., Isoquercitrin induces apoptosis and autophagy in hepatocellular carcinoma cells via AMPK/mTOR/p70S6K signaling pathway, Aging (Albany NY) 12 (2020) 24318-24332. https://doi.org/10.18632/aging.202237.

Crossref Google Scholar
[46]

K. Wang, R. Liu, J. Li, et al., Quercetin induces protective autophagy in gastric cancer cells: involvement of Akt-mTOR-and hypoxia-induced factor 1α-mediated signaling, Autophagy 7 (2011) 966-978. https://doi.org/10.4161/auto.7.9.15863.

Crossref Google Scholar
[47]

J.L. Chang, J.M. Chow, J.H. Chang, et al., Quercetin simultaneously induces G0/G1-phase arrest and caspase-mediated crosstalk between apoptosis and autophagy in human leukemia HL-60 cells, Environ. Toxicol. 32 (2017) 1857-1868. https://doi.org/10.1002/tox.22408.

Crossref Google Scholar
[48]

P.C.H. Hollman, J.M.P. van Trijp, M.J.B. Mengelers, et al., Bioavailability of the dietary antioxidant flavonol quercetin in man, Cancer Lett. 114 (1997) 139-140. https://doi.org/10.1016/s0304-3835(97)04644-2.

Crossref Google Scholar
[49]

S. Wolffram, M. Blöck, P. Ader, Quercetin-3-glucoside is transported by the glucose carrier SGLT1 across the brush border membrane of rat small intestine, J. Nutr. 132 (2002) 630- 635. https://doi.org/10.1093/jn/132.4.630.

Crossref Google Scholar
[50]

Z. Chen, S. Zheng, L. Li, et al., Metabolism of flavonoids in human: a comprehensive review, Curr. Drug Metab. 15 (2014) 48-61. https://doi.org/10.2174/138920021501140218125020.

Crossref Google Scholar
Food Science and Human Wellness
Volume 13 Issue 3,
May 2024
Pages 1698-1710
DOI: 10.26599/FSHW.2022.9250216
Cite this article:
Choi Y-J, Fan M, Wedamulla NE, et al. Alleviatory effect of isoquercetin on benign prostatic hyperplasia via IGF-1/PI3K/Akt/mTOR pathway. Food Science and Human Wellness, 2024, 13(3): 1698-1710. https://doi.org/10.26599/FSHW.2022.9250216
Metrics & Citations  
Article History
Copyright
Rights and Permissions
Return